全球神经调节设备市场 – 行业趋势和 2031 年预测

神经调节设备市场分析和规模

全球帕金森病患病率的上升是推动市场增长的主要因素之一。对医疗技术进步的关注度不断提高，加上临床试验数量的增加，是另一个市场增长的决定因素。医疗旅游业的兴起和神经刺激器批准率的上升将进一步创造有利可图的市场增长机会。

然而，与设备相关的高成本将阻碍市场增长率。缺乏医疗专家和不利的报销政策（尤其是在发展中和欠发达经济体）将进一步给市场带来挑战。此外，落后经济体缺乏意识和新兴经济体诊断和治疗率低将阻碍市场增长率。             

Data Bridge Market Research 分析，全球神经调节设备市场在 2023 年为 67 亿美元，到 2031 年可能达到 163.7 亿美元，预计在预测期内的复合年增长率为 11.80%。由于内部神经调节提供了强度和韧性，“内部神经调节”在市场的产品类型细分中占据主导地位。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的洞察外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。

神经调节设备市场范围和细分

市场定义

神经调节设备是在神经调节过程中使用的医疗器械，神经调节使用体内的电或化学药剂来刺激神经部位。神经调节用于治疗多种神经系统疾病，例如癫痫、阿尔茨海默病、脑血管病和帕金森病。

全球神经调节设备市场动态

驱动程序

• 慢性病患病率不断上升

慢性疼痛、神经系统疾病和运动障碍等慢性疾病的发病率不断上升，这是市场的重要推动力。神经调节疗法（包括脊髓刺激和深部脑刺激）为对传统药物疗法反应不佳的患者提供了替代治疗选择。

• 神经调节技术的进步

神经调节技术的持续研究和开发促进了市场的增长。设备设计、电极技术和刺激参数的创新提高了神经调节疗法的有效性和安全性。这些进步可能会促使开发出更有针对性和更精确的设备，从而扩大可治疗的疾病范围。

• 提高对神经调节疗法的认识和接受度

Growing awareness among both healthcare professionals and patients about the benefits of neuromodulation therapies contributes to market expansion. As more clinical evidence supports the efficacy and safety of these therapies, acceptance among physicians and patients is likely to increase. Patient education initiatives and collaborations between healthcare providers and device manufacturers also play a role in promoting the adoption of neuromodulation devices.

• Growing Investment for Healthcare Facilities

Surging focus on improving the condition of healthcare facilities and improving the overall healthcare infrastructure is another important factor fostering the growth of the market. The rising number of partnerships and strategic collaborations between the public and private players about funding and application of new and improved technology is further creating lucrative market opportunities.  

Opportunities

• Expanding Applications and Indications

There is an opportunity to explore and develop new applications and indications for neuromodulation devices. As the understanding of neural circuitry and the mechanisms of various disorders improves, neuromodulation therapies can be adapted for a broader range of conditions. Research and development efforts that expand the scope of neuromodulation to address conditions beyond chronic pain, such as psychiatric disorders and autoimmune diseases, could open new markets and revenue streams.

• Technological Innovations and Miniaturization

Continued advancements in technology, including miniaturization and the development of more sophisticated and targeted devices, present opportunities in the neuromodulation devices market. Smaller, implantable devices with enhanced capabilities may lead to increased patient acceptance, improved outcomes, and expanded applications. Innovations such as closed-loop systems that provide adaptive, real-time adjustments based on physiological feedback offer promising prospects for more effective and personalized treatments.

Restraints

• High Cost of Neuromodulation Devices

The cost of neuromodulation devices, including the initial implantation procedure and ongoing maintenance, can be substantial. This poses a challenge for widespread adoption, especially in regions with limited healthcare budgets or where reimbursement policies may not adequately cover the expenses. The high cost can be a barrier to access for some patients and limit market growth.

• Stringent Regulatory Approval Processes

The regulatory approval process for neuromodulation devices is often stringent and time-consuming. Obtaining approvals from regulatory authorities such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) involves extensive clinical trials and data submission. Delays in obtaining approvals can hinder the timely introduction of new devices to the market, affecting innovation and competitiveness.

Challenges

• Risk of Adverse Events and Complications

Neuromodulation procedures, like any surgical intervention, carry inherent risks of adverse events and complications. These may include infection, device malfunction, or unintended side effects. Concerns about the safety and long-term outcomes of neuromodulation therapies can impact patient and physician confidence, potentially leading to hesitancy in adopting these treatments.

• Limited Awareness and Understanding

Despite the potential benefits of neuromodulation therapies, there is often limited awareness and understanding among patients and even some healthcare professionals. This lack of awareness can result in underdiagnosis and underutilization of neuromodulation devices for treating certain conditions. Educational efforts are needed to increase awareness about the efficacy, safety, and appropriateness of neuromodulation therapies for various disorders.

This neuromodulation devices market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the neuromodulation devices market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In September 2023, PathMaker Neurosystems Inc. started a human clinical trial for its MyoRegulator device developed for the treatment of amyotrophic lateral sclerosis (ALS)
• In July 2023, Slavia BioElectronics reported the first implantation of its paper-thin neuromodulation bioelectronic foils for the treatment of severe migraine and cluster headaches

Global Neuromodulation Devices Market Scope

The neuromodulation devices market is segmented on the basis of product type, end user, application and biomaterial. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

• Internal Neuromodulation
• External Neuromodulation

Application                                                                     

• Spinal Cord Stimulation
• Deep Brain Stimulation
• Sacral Nerve Stimulation
• Vagus Nerve Stimulation
• Gastric Electrical Stimulation
• Transcutaneous Electrical Nerve Stimulation
• Repetitive Transcranial Magnetic Stimulation
• Respiratory Electrical Stimulation

End user

• Hospitals
• Clinics
• Home Healthcare
• Others

Biomaterial

• Metallic Biomaterials
• Polymeric Biomaterials
• Ceramic Biomaterials

Global Neuromodulation Devices Market Regional Analysis/Insights

The neuromodulation devices market is analyzed and market size insights and trends are provided by country, product type, end user, application and biomaterial as referenced above.

The countries covered in the market report are the U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Russia, Poland, Switzerland, Netherlands, Hungary, Austria, Norway, Ireland, Turkey, Lithuania, rest of Europe, China, Japan, India, Australia, South Korea, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, rest of Asia-Pacific, Brazil, Argentina, Peru, rest of South America, South Africa, Saudi Arabia, U.A.E., Israel, Egypt, and rest of Middle East & Africa.

North America is expected to dominate the market due to the prevalence of favourable reimbursement policies. Asia-Pacific is expected to exhibit the highest growth rate during the forecast period due to the growth and expansion of healthcare industry in this region, ever-rising geriatric population and growth in the number of neurological disorders.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The neuromodulation devices market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for neuromodulation devices market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the neuromodulation Devices market. The data is available for historic period 2010-2020.

Competitive Landscape and Global Neuromodulation Devices Market Share Analysis

The neuromodulation devices market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to neuromodulation devices market.

Some of the major players operating in the neuromodulation devices market are:

• Medtronic (Ireland)
• Boston Scientific Corporation (U.S.)
• Stryker (U.S.)
• Abbott (U.S.)
• B.Braun Melsungen AG（德国）
• NEVRO CORP.（美国）
• NeuroSigma, Inc.（美国）
• NeuroPace, Inc.（美国）
• Soterix Medical Inc.（美国）
• Synapse Biomedical Inc.（美国）
• ReShape Lifesciences, Inc.（美国）
• Bioness Inc.（美国）
• ALEVA NEUROTHERAPEUTICS SA（瑞士）
• LivaNova PLC（英国）
• 神经元学。（美国）
• Cyber​​onics, Inc.（美国）
• Neuromod（爱尔兰）
• Axonics, Inc.（美国）
• Magstim 有限公司 (英国)
• Sooma Medical（芬兰）

SKU-47959